Turnstone Biologics (NASDAQ:TSBX) Posts Earnings Results, Beats Estimates By $0.13 EPS

Turnstone Biologics (NASDAQ:TSBX) posted its quarterly earnings results on Tuesday. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.13, Zacks reports.

Turnstone Biologics Price Performance

Shares of Turnstone Biologics stock opened at $0.53 on Thursday. The stock has a market cap of $12.35 million, a price-to-earnings ratio of -0.16 and a beta of 2.21. The firm’s 50-day moving average is $0.54 and its two-hundred day moving average is $1.69. Turnstone Biologics has a 1 year low of $0.44 and a 1 year high of $5.75.

Analyst Upgrades and Downgrades

TSBX has been the topic of a number of research reports. Piper Sandler reduced their target price on shares of Turnstone Biologics from $20.00 to $3.75 and set an “overweight” rating on the stock in a research report on Monday, August 19th. Bank of America cut Turnstone Biologics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $10.00 to $0.50 in a research note on Monday, October 14th.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.